option

Thermobalancing therapy emerges as drug-free option for BPH, chronic prostatitis, back pain and kidney stones

Oxford, UK, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Therapeutic Dr Allen’s Devices are designed to treat different chronic health conditions,…

3 days ago

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

February 20, 2026 15:10 ET  | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia…

3 days ago

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical…

4 days ago

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical…

2 weeks ago

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

January 23, 2026 17:00 ET  | Source: Corvus Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) --…

1 month ago

IQ Option Marks Its 12th Anniversary and Launches a $56,000 Tournament

ST. JOHN'S, Antigua and Barbuda, Dec. 3, 2025 /PRNewswire/ -- The online trading platform IQ Option is celebrating its 12th anniversary,…

3 months ago

Hydreight Technologies Acquires 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase up to 40%, and Establishes Strategic Partnership

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Nov. 28,…

3 months ago

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares for Gross Proceeds of $345 Million

SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

5 months ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41)…

5 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

5 months ago